



Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 2, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 2, 2025-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will participate at the H.C. Wainwright 27th Annual Global Investment Conference. Access to the company's presentation will be available on Friday, September 5, 2025 beginning at 7:00 a.m. Eastern Time.

A webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.

About Quince Therapeutics

Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince on social media platforms [LinkedIn](#), [Facebook](#), [X](#), and [YouTube](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20250902882769/en/>

Media & Investor Contact:

Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
ir@quincetx.com

Source: Quince Therapeutics, Inc.